"Pharmaceutical Express" Hengrui SHR-1314 approved clinical FDA delayed liso-cel listing application

November 17, 2020 / Medical Information At a Glance: Schweija China Operations Director Robert Lo is leaving; FDA again postpones liso-cel listing application; East China Pharmaceutical Injection sodium sodium is evaluated; Hengrui SHR-1314 monoantigen approved clinical ... Daily fresh medicine news, speed reading society and you pay attention to! Part 1 policy brief 375 collection of unseeded drugs will be reduced prices recently, Jilin Province Public Resources Trading Center issued "on the publicity of the third batch of national organizations centralized procurement and use of drugs not selected Jilin Province and not selected and has participated in Jilin Province online procurement of some drug prices linked price reduction results notice."
, a total of 375 drugs began to reduce prices, including domestic and foreign well-known pharmaceutical companies products.
(Jilin Province Public Resources Trading Center) Part 2 after watching Lilly co-development of RNAi gene therapy new drug application authorized November 16, RNA Interference (RNAi) gene therapy drug developer Dicerna announced that the U.S. FDA has authorized the development of a new drug code-named LY3561774, Dierna and Lilly's first clinical phase drug candidate.
(Sina Pharmaceutical News) Schweinstinger China Operations Director Rob Li left today, Schweija China General Manager Stephane Mascarau announced a personnel change to employees, and now Schweija China Operations Director Lloyd Bradley has been promoted to general manager of Schweija Australia, where he will leave China for Australia next month.
(Pharmaceutical Representative) Prijin completed the 140 million yuan B round of financing and the launch of the Hong Kong stock IPO, cell therapy company Prikin announced the completion of 140 million yuan B round of fund raising, and start the Hong Kong stock IPO process.
current product line includes TCR-T, CAR-T, stem cells, etc., and several products are in the process of FDA IND declaration.
(Medical Valley) Part 3 Drug News Johnson and Johnson launched JNJ-78436735 second-in-the-nation new crown vaccine phase III clinical days ago, Johnson and Johnson's Jansen developed the new crown vaccine Ad26.COV2.S (also known as J NJ-78436735) is in the late stages of trial, and early data have shown that patients can develop an immune response after injecting a dose of JNJ-78436735, but now the company hopes to be able to evaluate the efficacy of the secondary vaccine solution through trials.
(Xinhua) -- The FDA again delayed the listing of liso-cel on November 16, BMS announced that the FDA has notified the company that the biopic license review for the company's lisocabtagene maraluel (lisocabtagene maraluel) for the treatment of adult recurring or incurable large B-cell lymphoma will not be completed on November 16, 2020.
(Sina Pharmaceutical News) Moderna's new crown candidate vaccine has a protective power of 94.5 percent Today, Moderna announced that its new crown candidate vaccine mRNA-1273 based on mRNA technology has reached the primary efficacy endpoint in the first interim analysis of COVE in Phase 3 clinical trials.
mRNA-1273 was 94.5% effective in protecting COVID-19 diseases with symptoms.
(Pharmaceutical Mingkangde) innovative therapy vixarelimab by the FDA breakthrough therapy kiniksa company announced today, the U.S. FDA has awarded the in-research therapy vixarelimab breakthrough therapy identified for the treatment of itching associated with nodding itching.
Vixarelimab is an all-human monoclonal antibody that targets the tumor-suppressor M β.
RNAi Therapy announced the latest results Today, Dicerna Pharmaceuticals announced the results of phase 1 clinical trials of RNAi Therapy RG6346, developed in collaboration with Roche to treat HBV infection, showing a significant and lasting reduction in the biomarkers of HBV disease activity with RG6346 treatment once a month.
HBsAg levels can continue to decrease for up to 1 year after the last drug is given.
(Pharmaceutical Mingkangde) East China Medicine injection sodium, the Official Website of the State Drug Administration shows that Hangzhou Sino-American East China Pharmaceutical injection sodium through consistent evaluation of supplementary applications.
totraazole is a proton pump inhibitor widely used in clinical applications, mainly used to treat gastritis, stomach erosion, peptic ulcers, reflowal esophagitis, Zoai syndrome and so on.
(Minenet) True Alliance Pharmaceutical Anti-HBV nuclear casing inhibitor ZM-H1505R was approved clinically on November 16, CDE publicity, Shanghai Union Pharmaceutical Technology Co., Ltd. declared a class 1 new drug ZM-H1505R obtained clinical trial implied permission, intended to carry out safety and anti-hepatitis B virus effectiveness trials in patients with chronic hepatitis B.
(Pharmaceutical Rubik's Cube) and Platinum Pharmaceutical Dry Eye Disease Phase 2 results will be published on November 16, and Platinum Pharmaceuticals announced that it will be held at the upcoming 25th National Ophthalmology Conference of the Chinese Medical Association, the Tynasip (HBM9036) eye drops for patients with moderate to severe dry eye disease in China clinical Phase 2 results.
(Pharmaceutical Mission) treatment of heart failure drug Giancon PDE9 inhibitor approved clinically in China on November 16, CDE announced that the drug Giankang's class 1 new drug TT-00920 tablets obtained 3 clinical trials implied license, intended to be developed for heart failure.
public information, TT-00920 has previously been approved for clinical use in the United States.
(Pharmaceutical Mission) Hengrui SHR-1314 single-resistance approved clinical November 16, Hengrui Pharma announced that its own research and development of a new class of 1 drug SHR-1314 was issued by NMPA "Drug Clinical Trial Approval Notice", allowing the development of strong-straight spina boutitis adaptation clinical trials.
(Insight Database) Somalutide joint cilofexo/firsocostat treatment NASH II received positive results on November 15, Gilead/Noor and Nord jointly published the results of the Phase II concept validation study.
the study reached its main clinical endpoint, NASH patients with mild and moderate liver fibrosis were well-resistant to all treatment options.
, the indicators of liver fatty degeneration and liver injury in the combined treatment group improved statistically compared with the single drug treatment group of Somaglutide.
common myalgia problem is not a recent clinical trial published at the 2020 Scientific Conference on statin pharmacological side effects, showing that patients taking statins and placebos experience similar adverse reactions.
that this is mainly caused by the "antisabo effect, not the actual pharmacological effect of the drug."
(Medical New Perspective) NEJM released data in 9 countries to support the "multi-in-one" drug, based on the compound drug concept of another heavy study TIPS-3 announced results. data from
across nine countries, covering more than 5,700 subjects, showed that taking multiple drugs containing four lipid-lowering, anti-hyperpressin and low-dose aspirins daily reduced the risk of heart attack, stroke and heart-related death by about a third.
(Medical New View point)